The report mentions the negative impact of the Deep and Comprehensive Free Trade Agreement negotiated between the Republic of Moldova and the European Union on access to accessible medicines. This agreement will prevent the manufacturers of generic drugs to provide cheaper alternatives to originator drugs because of data exclusivity provisions.
Citation: Anand Grover, 'Communications Report of the Special Rapporteur on the right to health: Moldova' (2012) OTH 9/2012